Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06577935 · ClinicalTrials.gov registry record · Phase 2
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
A Phase 2 study of Postmenopausal Osteoporosis, sponsored by Angitia Biopharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 379
- Enrollment target
- 20
- Study locations
NCT06577935: Active Phase 2 study of Postmenopausal Osteoporosis, sponsored by Angitia Biopharmaceuticals.
NCT06577935 is a Phase 2 study of Postmenopausal Osteoporosis that is active but no longer recruiting, run by Angitia Biopharmaceuticals. The registered enrollment target is 379 participants, below the 494-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (23% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06577935, a Phase 2 study of Postmenopausal Osteoporosis, is active but no longer recruiting, sponsored by Angitia Biopharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 379 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.
Primary Outcome
To determine the effect of treatment with AGA2118 versus placebo at Month 12 on the percent change from Baseline in bone mineral density at the lumbar spine in postmenopausal women with low bone mineral density
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AGA2118
Study Locations (20)
Other
- CIDIIM - Córdoba
- Centro de Investigaciones Medicas Mar del Plata CIM - Mar del Plata
- Futuremeds Gdynia - Gdynia
- Krakowskie Centrum Medyczne - Krakow
- Futuremeds Lodz - Lodz
- Futuremeds Warszawa Centrum - Warsaw
- Futuremeds Targowek - Warsaw
- Futuremeds Wroclaw - Wroclaw
Argentina
- Centro Médico Dra Laura Maffei e Investigación Cliínica Aplicada - Buenos Aires
- Consultorio de Investigacion Clinica EMO SRL - Buenos Aires
- IDIM - Buenos Aires
- Investigaciones Reumatologicas y Osteologicas SRL - Buenos Aires
- Mautalen - Salud e Investigacion (Expertia S.A.) - Buenos Aires
- Stat Research - Buenos Aires
- Instituto Médico Strusberg - Córdoba
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Center for Advanced Research & Education - Gainesville
New Mexico
- NM Clinical Research & Osteoporosis Center, Inc. - Albuquerque
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
Washington
- Puget Sound Osteoporosis Center - Burien
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 379 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
What the registry record for NCT06577935 still lists
NCT06577935 is an interventional study that assigns participants to a tested intervention. The registered 379 participants enrollment target is mid-sized for trials with a published cap, below the 494-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06577935 names 20 study sites across 7 states, led by Other, Argentina, Alabama.
Frequently Asked Questions
What is clinical trial NCT06577935 about?
NCT06577935 is a clinical study titled "A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)". The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.
What is the current status of trial NCT06577935?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 379 participants. The study started on 2024-10-31. Estimated completion is 2028-03.
What conditions does trial NCT06577935 study?
This clinical trial studies the following conditions: Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT06577935?
The interventions under investigation include: Placebo (OTHER), AGA2118 (DRUG).
Who is sponsoring clinical trial NCT06577935?
This trial is sponsored by Angitia Biopharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06577935 being conducted?
This trial has 20 study locations across Alabama, Georgia, New Mexico, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06577935's enrollment target sits among peer trials
379 8th of 14 higher than 7 of 14 other Postmenopausal Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postmenopausal Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
COMPLETED · Phase 2
-
Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
COMPLETED · Phase 2
-
Dried Plums and Bone Health in Postmenopausal Women
ACTIVE NOT RECRUITING · NA
-
Anabolic Therapy in Postmenopausal Osteoporosis
ACTIVE NOT RECRUITING · Phase 4
-
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
-
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI